In HER-2-positive breast cancer models, trastuzumab-grafted poly(amidoamine) dendrimers encapsulating docetaxel showed a higher cytotoxic effect than non-grafted dendrimers or conventional docetaxel (Taxotere®) in MDA-MB-453 cells (they overexpress HER-2 receptors), with IC50 values of 56.18 ng/mL, 201 ng/mL, and >250 ng/mL, respectively. Here, ERBB2 is linked to breast carcinoma.